FMC Biopolymer AS

Norway

Back to Profile

1-18 of 18 for FMC Biopolymer AS Sort by
Query
Patent
Aggregations Reset Report
Jurisdiction
        World 12
        United States 5
        Canada 1
IPC Class
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters 4
A61L 27/20 - Polysaccharides 4
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin 3
A61K 9/00 - Medicinal preparations characterised by special physical form 3
A61K 9/16 - AgglomeratesGranulatesMicrobeadlets 3
See more
Found results for  patents

1.

HYDROGEL COMPRISING MANGANESE, METHODS AND USES THEREOF

      
Application Number IB2018060532
Publication Number 2019/123423
Status In Force
Filing Date 2018-12-21
Publication Date 2019-06-27
Owner
  • ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECHNOLOGIES & THERAPIES (A4TEC) ASSOCIAÇÃO (Portugal)
  • MOSSAKOWSKI MEDICAL RESEARCH CENTRE POLISH ACADEMY OF SCIENCES (Poland)
  • UNIWERSYTET WARMIŃSKO-MAZURSKI W OLSZTYNIE (Poland)
  • FMC BIOPOLYMER AS (Norway)
Inventor
  • Antunes Correia De Oliveira, Joaquim Miguel
  • Araújo Vieira, Sílvia Cristina
  • Moreira Pinheiro Dos Santos Oliveira, Maria Eduarda
  • Da Silva Correia De Oliveira, Joana Catarina
  • Gonçalves Dos Reis, Rui Luís
  • Walczak, Piotr
  • Malysz-Cymborska, Izabela
  • Golubczyk, Dominika
  • Kalkowski, Lukasz
  • Majchrzak, Malgorzata
  • Janowski, Miroslaw
  • Strymecka, Paulina Natalia
  • Stanaszek, Luiza
  • Lukomska, Barbara
  • Svendsen, Terje
  • Asdahl, Lise Cathrine
  • Myhr Sætrang, Henriette Elisabeth

Abstract

The present disclosure relates to biocompatible ionically crosslinked hydrogel polymers comprising polysaccharides such as alginate, hyaluronic acid, gellan gum or its derivatives and manganese ions for use in medicine, in particular for imaging purposes. Therefore, the hydrogel present disclosure is useful for spatio-temporal control of cells/drugs delivery in a wide range of therapeutic applications.

IPC Classes  ?

  • A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/06 - OintmentsBases therefor
  • A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 9/70 - Web, sheet or filament bases

2.

Self-gelling alginate systems and uses thereof

      
Application Number 14288767
Grant Number 09463162
Status In Force
Filing Date 2014-05-28
First Publication Date 2014-09-18
Grant Date 2016-10-11
Owner FMC Biopolymer AS (Norway)
Inventor
  • Melvik, Jan Egil
  • Dornish, Michael
  • Onsoyen, Edvar
  • Berge, Astrid B.
  • Svendsen, Terje

Abstract

Kits and compositions for producing an alginate gel are disclosed. The kits and compositions comprise soluble alginate and insoluble alginate/gelling ion particles. Methods for dispensing a self-gelling alginate dispersion are disclosed. The methods comprise forming a dispersion of insoluble alginate/gelling ion particles in a solution containing soluble alginate, and dispensing the dispersion whereby the dispersion forms an alginate gel matrix. The methods may include dispensing the dispersion into the body of an individual. An alginate gel having a thickness of greater than 5 mm and a homogenous alginate matrix network and homogenous alginate gels free of one or more of: sulfates citrates, phosphates, lactatates, EDTA or lipids are disclosed. Implantable devices comprising a homogenous alginate gel coating are disclosed. Methods of improving the viability of pancreatic islets, or other cellular aggregates or tissue, following isolation and during storage and transport are disclosed.

IPC Classes  ?

  • A61K 35/32 - BonesOsteocytesOsteoblastsTendonsTenocytesTeethOdontoblastsCartilageChondrocytesSynovial membrane
  • A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
  • A61L 27/20 - Polysaccharides
  • C08L 5/04 - Alginic acidDerivatives thereof
  • A61K 9/10 - DispersionsEmulsions
  • A23L 1/0532 - from seaweeds, e.g. alginates, agar, carrageenan
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
  • A61K 31/729 - AgarAgaroseAgaropectin
  • A61L 27/34 - Macromolecular materials
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 27/38 - Animal cells
  • A61L 29/08 - Materials for coatings
  • A61L 31/10 - Macromolecular materials
  • A61K 31/734 - Alginic acid
  • A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

3.

Self-gelling alginate systems and uses thereof

      
Application Number 13930426
Grant Number 08741872
Status In Force
Filing Date 2013-06-28
First Publication Date 2013-10-31
Grant Date 2014-06-03
Owner FMC Biopolymer AS (Norway)
Inventor
  • Melvik, Jan Egil
  • Dornish, Michael
  • Onsoyen, Edvar
  • Berge, Astrid B.
  • Svendsen, Terje

Abstract

Kits and compositions for producing an alginate gel are disclosed. The kits and compositions comprise soluble alginate and insoluble alginate/gelling ion particles. Methods for dispensing a self-gelling alginate dispersion are disclosed. The methods comprise forming a dispersion of insoluble alginate/gelling ion particles in a solution containing soluble alginate, and dispensing the dispersion whereby the dispersion forms an alginate gel matrix. The methods may include dispensing the dispersion into the body of an individual. An alginate gel having a thickness of greater than 5 mm and a homogenous alginate matrix network and homogenous alginate gels free of one or more of: sulfates citrates, phosphates, lactates, EDTA or lipids are disclosed. Implantable devices comprising a homogenous alginate gel coating are disclosed. Methods of improving the viability of pancreatic islets, or other cellular aggregates or tissue, following isolation and during storage and transport are disclosed.

IPC Classes  ?

4.

Self-gelling alginate systems and uses thereof

      
Application Number 12855964
Grant Number 08481695
Status In Force
Filing Date 2010-08-13
First Publication Date 2010-12-02
Grant Date 2013-07-09
Owner FMC Biopolymer AS (Norway)
Inventor
  • Melvik, Jan Egil
  • Dornish, Michael
  • Onsoyen, Edvar
  • Berge, Astrid B.
  • Svendsen, Terje

Abstract

Kits and compositions for producing an alginate gel are disclosed. The kits and compositions comprise soluble alginate and insoluble alginate/gelling ion particles. Methods for dispensing a self-gelling alginate dispersion are disclosed. The methods comprise forming a dispersion of insoluble alginate/gelling ion particles in a solution containing soluble alginate, and dispensing the dispersion whereby the dispersion forms an alginate gel matrix. The methods may include dispensing the dispersion into the body of an individual. An alginate gel having a thickness of greater than 5 mm and a homogenous alginate matrix network and homogenous alginate gels free of one or more of: sulfates citrates, phosphates, lactatates, EDTA or lipids are disclosed. Implantable devices comprising a homogenous alginate gel coating are disclosed. Methods of improving the viability of pancreatic islets, or other cellular aggregates or tissue, following isolation and during storage and transport are disclosed.

IPC Classes  ?

  • C08B 37/04 - Alginic acidDerivatives thereof
  • C07H 1/00 - Processes for the preparation of sugar derivatives
  • A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters

5.

OLIGONUCLEOTIDE NON-VIRAL DELIVERY SYSTEMS

      
Application Number EP2007059740
Publication Number 2008/031899
Status In Force
Filing Date 2007-09-14
Publication Date 2008-03-20
Owner FMC BIOPOLYMER AS (Norway)
Inventor
  • Artursson, Per Artur Sven
  • Issa, Mohamed Mahmoud
  • Strand, Sabina Prochazkova
  • Varum, Kjell Morten

Abstract

Low molecular weight low molecular weight chitosan oligomers were able to self- assemble siRNA into nanosized particles, provide protection against enzymatic degradation, and mediate gene silencing that is stable over a long period of time in vitro. The control of structural variables in formulating complexes of siRNA with low molecular weight chitosans provides an efficient alternative delivery system for siRNA in vitro and in vivo.

IPC Classes  ?

  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
  • C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

6.

HYDROGELS CONTAINING LOW MOLECULAR WEIGHT ALGINATES AND BIOSTRUCTURES MADE THEREFROM

      
Application Number EP2007055856
Publication Number 2008/006658
Status In Force
Filing Date 2007-06-13
Publication Date 2008-01-17
Owner
  • FMC BIOPOLYMER AS (Norway)
  • MCCALL, John D. (United Kingdom)
Inventor
  • Melvik, Jan Egil
  • Gaserod, Olav

Abstract

The present invention is directed to a hydrogel comprising an alginate having a low molecular weight (e.g., less than 75,000 Daltons), wherein the alginate is present in a high concentration (e.g., greater than 2.5% by weight of the hydrogel). The present invention is also directed to methods of making and using the hydrogel, as well as products containing the hydrogel.

IPC Classes  ?

  • A61K 9/06 - OintmentsBases therefor
  • A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 33/00 - Medicinal preparations containing inorganic active ingredients
  • A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
  • A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K 49/00 - Preparations for testing in vivo

7.

GASTRO-ACTIVATED DIETARY FIBERS

      
Application Number IB2007001627
Publication Number 2007/148197
Status In Force
Filing Date 2007-06-18
Publication Date 2007-12-27
Owner FMC BIOPOLYMER AS (Norway)
Inventor Gaserod, Olav

Abstract

A gastro-activated dietary fiber comprising an insoluble polysaccharide salt and use of the gastro-activated dietary fiber in ingestible products. The gastro- activated dietary fibers may include salts of biopolymers such as alginates, carrageenans and pectins that are insoluble in water and exhibit minimal or no swelling in water. The water swelling ratio of the gastro-activated dietary fiber may 15 or less. The gastro-activation of the dietary fiber may be induced by exposure to an acidic pH of 3 or less for at least 15 minutes. Ingestible compositions containing the gastro-activated dietary fiber solubilize and provide a viscosity increase in the digestive tract as a result of activation of the dietary fiber by natural excretions of the small intestine which induce gelation of the dietary fiber. Beneficial health effects are potentially obtained by the provision of dietary fiber in this manner, without the usual disadvantages of reduced palatability and poor mouthfeel that are associated with soluble fiber-containing ingestible compositions.

IPC Classes  ?

  • A23L 1/308 - Addition of substantially indigestible substances, e.g. dietary fibres (A23L 1/05 takes precedence);;
  • A23L 1/09 - containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin (A23L 1/76, A23L 1/236 take precedence);;
  • A23L 1/0524 - Pectin; Derivatives thereof
  • A23L 1/0528 - from corms, tubers or roots, e.g. glucomannan (A23L 1/522 takes precedence);;
  • A23L 1/0532 - from seaweeds, e.g. alginates, agar, carrageenan
  • A23L 2/52 - Adding ingredients
  • A21D 2/18 - Carbohydrates

8.

METHODS AND APPARATUS FOR USING POLYMER-BASED BEADS AND HYDROGELS FOR CARDIAC APPLICATIONS

      
Application Number US2007013844
Publication Number 2007/146319
Status In Force
Filing Date 2007-06-13
Publication Date 2007-12-21
Owner
  • SYMPHONY MEDICAL, INC. (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • FMC BIOPOLYMER AS (Norway)
Inventor
  • Lee, Randall, J.
  • Rauh, Francis
  • Maciejewski, Mark

Abstract

Biopolymer beads and hydrogels are useful in the remodeling, repair and reconstruction of the heart, as well as in modification of electrical conduction in the heart. Various types of beads are useful, including beads comprising a core of alginate polymers which may or may not be bonded to peptides; beads comprising a core in which peptides are dispersed with alginate polymers, and a chitosan film ionically bonded to available alginate polymers at the surface of the core; beads comprising a core in which peptides and chitosan derivates are dispersed with alginate polymers and form alginate-peptide complexes to which the chitosan derivatives are bonded; and beads comprising a core of chitosan polymers which may or may not be bonded to peptides. The heart may also be treated with a hydrogel agent comprising alginate polymers and peptides covalently bonded to the alginate polymers.

IPC Classes  ?

  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets

9.

METHOD AND SYSTEMS FOR USING BIOPOLYMER-BASED BEADS AND HYDROGELS

      
Application Number US2007071142
Publication Number 2007/147014
Status In Force
Filing Date 2007-06-13
Publication Date 2007-12-21
Owner FMC BIOPOLYMER AS (Norway)
Inventor
  • Rauh, Francis
  • Lee, Randall, J.
  • Maciejewski, Mark

Abstract

Compositions comprising biopolymers such as alginates and cell attachment peptides are disclosed. Compositions may optionally further comprise cells. Methods for repairing or treating a tissues and organs with such compositions and systems for providing such compositions to tissues and organs, and methods for delivering desired proteins to individual with such compositions and systems for providing such compositions are also disclosed. In vitro methods of culturing cells are also disclosed.

IPC Classes  ?

  • C08L 5/00 - Compositions of polysaccharides or of their derivatives not provided for in group or
  • A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

10.

ALGINATE COATED, COLLAGEN MATRIX CELLULAR DEVICE, PREPARATIVE METHODS, AND USES THEREOF

      
Application Number EP2007055857
Publication Number 2007/144389
Status In Force
Filing Date 2007-06-13
Publication Date 2007-12-21
Owner FMC BIOPOLYMER AS (Norway)
Inventor
  • Dufrane, Denis
  • Gianello, Pierre Rene Raymond
  • Melvik, Jan Egil

Abstract

The present invention is directed to cellular devices comprising a collagen matrix, cell layer, and gelled alginate layer, processes for producing the devices, methods of implanting the devices, and methods of treatment thereof.

IPC Classes  ?

  • C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor

11.

A FOAM AND USE THEREOF

      
Application Number US2007005326
Publication Number 2007/123598
Status In Force
Filing Date 2007-03-01
Publication Date 2007-11-01
Owner FMC BIOPOLYMER AS (Norway)
Inventor
  • Dornish, Michael
  • Andersen, Therese
  • Melvik, Jan, Egil

Abstract

The invention provides a method of producing a gelled foam comprising the steps of: forming a dispersion by mixing i) a solution comprising a soluble polysaccharide and a plasticizer and adding a polysaccharide/gel-forming ion particles or ii) a soluble, preferably immediately soluble, polysaccharide, preferably an alginate, a polysaccharide /gel-forming ion particles, and adding a solvent, said dispersion (ii) further comprising a water soluble plasticizer to make the dispersion and then aerating the dispersion to form the foam. The foam may be inhomogeneous in structure which is useful in providing improved delivery of a component carried in the foam and in degradation.

IPC Classes  ?

  • C08J 9/12 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent

12.

GELLED COMPOSITE

      
Application Number US2007005436
Publication Number 2007/103209
Status In Force
Filing Date 2007-03-01
Publication Date 2007-09-13
Owner
  • FMC BIOPOLYMER AS (Norway)
  • FMC CORPORATION (USA)
Inventor
  • Gaserod, Olav
  • Andersen, Therese
  • Melvik, Jan, Egil
  • Dornish, Michael
  • Riley, Peter, J.

Abstract

The invention relates to composites comprising a polysaccharide gelled within pores of a foam, methods of preparation, and uses thereof, for example, in biomedical applications such as cell culture media and implants, controlled release delivery systems, food applications, industrial applications, and personal care applications such as cosmetic and oral hygiene. The composites of the present invention are simple to formulate using few steps and are useful for entrapping heat-sensitive components, such as cells, drugs, flavors or fragrances within the polysaccharide gel. In addition, the invention provides for a composite able to gently immobilize fragile components, such as living cells, without exposing such components to shear forces.

IPC Classes  ?

  • A61L 27/20 - Polysaccharides
  • A61L 27/38 - Animal cells
  • A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
  • A61L 27/56 - Porous or cellular materials

13.

BIODEGRADABLE FOAM

      
Application Number US2007005435
Publication Number 2007/103208
Status In Force
Filing Date 2007-03-01
Publication Date 2007-09-13
Owner
  • FMC BIOPOLYMER AS (Norway)
  • FMC CORPORATION (USA)
Inventor
  • Andersen, Therese
  • Kristiansen, Are
  • Joslin, Sara

Abstract

The invention relates to a method for forming a dried absorbent foam having an open pore network and pores by preparing an aqueous dispersion comprising an enzymatically biodegradable biopolymer and a foaming agent and optionally one or more of gel-forming ions, a plasticizer, a crosslinking agent and a pH modifier, forming, preparing or mixing a foam from the aqueous dispersion and drying the foam to form a dried foam containing open pores. Gelled composites made from the foams are also provided. The invention is particularly useful in providing foams and composites for use in biomedical applications and as an anti-adhesive in tissue regeneration and wound management.

IPC Classes  ?

  • A61L 27/20 - Polysaccharides
  • A61L 27/38 - Animal cells
  • A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
  • A61L 27/56 - Porous or cellular materials

14.

GELLING COMPOSITIONS AND METHODS

      
Application Number EP2006009614
Publication Number 2007/039294
Status In Force
Filing Date 2006-10-04
Publication Date 2007-04-12
Owner FMC BIOPOLYMER AS (Norway)
Inventor
  • Richardson, Johnathan, Craig
  • Dettmar, Peter, William
  • Gaserod, Olav
  • Helgerud, Trond

Abstract

A method for the administration of a composition that augments the acidity of gastric fluid such that intra-gastric gelation of the polysaccharide:acid soluble multivalent cation formulation is initiated independent of endogenous acid secretion. The composition includes: (a) at least one of a polysaccharide, modified polysaccharide, or polysaccharide salt, each capable of ionotropic gelation, (b) at least one source of multivalent cations capable of solubilization at an acidic pH, and (c) at least one acid component capable of providing a controlled release of protons sufficient to solubilize the multivalent cations. The composition is capable of hydrating in aqueous media and subsequently forming a gel in a stomach when ingested, which gel resists peristaltic forces and remains in the stomach for an extended time. Also disclosed are edible compositions including this composition, as well as methods of inducing a satiety effect and providing controlled release of various components employing the composition of the invention.

IPC Classes  ?

  • A23L 1/29 - Modifying nutritive qualities of foods; Dietetic products ( A23L 1/09 takes precedence;dietetic salt substitutes A23L 1/22)
  • A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
  • A61K 9/00 - Medicinal preparations characterised by special physical form

15.

MEDICAL DEVICES COATED WITH A FAST DISSOLVING BIOCOMPATIBLE COATING

      
Application Number US2006027425
Publication Number 2007/015761
Status In Force
Filing Date 2006-07-14
Publication Date 2007-02-08
Owner FMC BIOPOLYMER AS (Norway)
Inventor
  • Dornish, Michael
  • Larsen, Christian, Klein
  • Andersen, Therese

Abstract

The present invention relates to a medical device comprising a biocompatible medical coating adhered thereto, wherein the coating comprises at least one of a non-crosslinked, water soluble salt of: (i) alginic acid, (ii) hyaluronic acid or (iii) chitosan, wherein the coating is readily dissolvable in at least one mammalian body fluid.

IPC Classes  ?

  • A61L 27/20 - Polysaccharides
  • A61L 27/58 - Materials at least partially resorbable by the body
  • A61L 31/00 - Materials for other surgical articles
  • A61L 27/34 - Macromolecular materials
  • A61L 29/04 - Macromolecular materials
  • A61L 31/08 - Materials for coatings
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61L 29/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material

16.

Self-gelling alginate systems and uses thereof

      
Application Number 11248984
Grant Number 07790699
Status In Force
Filing Date 2005-10-12
First Publication Date 2006-07-20
Grant Date 2010-09-07
Owner FMC Biopolymer AS (Norway)
Inventor
  • Melvik, Jan-Egil
  • Dornish, Michael
  • Onsoyen, Edvar
  • Berge, Astrid B.
  • Svendsen, Terje

Abstract

Kits and compositions for producing an alginate gel are disclosed. The kits and compositions comprise soluble alginate and insoluble alginate/gelling ion particles. Methods for dispensing a self-gelling alginate dispersion are disclosed. The methods comprise forming a dispersion of insoluble alginate/gelling ion particles in a solution containing soluble alginate, and dispensing the dispersion whereby the dispersion forms an alginate gel matrix. The methods may include dispensing the dispersion into the body of an individual. An alginate gel having a thickness of greater than 5 mm and a homogenous alginate matrix network and homogenous alginate gels free of one or more of: sulfates citrates, phosphates, lactatates, EDTA or lipids are disclosed. Implantable devices comprising a homogenous alginate gel coating are disclosed. Methods of improving the viability of pancreatic islets, or other cellular aggregates or tissue, following isolation and during storage and transport are disclosed.

IPC Classes  ?

  • A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
  • C08B 37/04 - Alginic acidDerivatives thereof
  • C07G 3/00 - Glycosides

17.

SELF-GELLING ALGINATE SYSTEMS AND USES THEREOF

      
Document Number 02583373
Status In Force
Filing Date 2005-10-12
Open to Public Date 2006-04-27
Grant Date 2013-09-03
Owner FMC BIOPOLYMER AS (Norway)
Inventor
  • Melvik, Jan-Egil
  • Dornish, Michael
  • Onsoyen, Edvar
  • Berge, Astrid B.
  • Svendsen, Terje

Abstract

Kits and compositions for producing an alginate gel are disclosed. The kits and compositions comprise soluble alginate and insoluble alginate/gelling ion particles. Methods for dispensing a self-gelling alginate dispersion are disclosed. The methods comprise forming a dispersion of insoluble alginate/gelling ion particles in a solution containing soluble alginate, and dispensing the dispersion whereby the dispersion forms an alginate gel matrix. The methods may include dispensing the dispersion into the body of an individual. An alginate gel having a thickness of greater than 5 mm and a homogenous alginate matrix network and homogenous alginate gels free of one or more of: sulfates citrates, phosphates, lactatates, EDTA or lipids are disclosed. Implantable devices comprising a homogenous alginate gel coating are disclosed. Methods of improving the viability of pancreatic islets, or other cellular aggregates or tissue, following isolation and during storage and transport are disclosed.

IPC Classes  ?

18.

Polysaccharide capsules and methods of preparation

      
Application Number 10509980
Grant Number 07972620
Status In Force
Filing Date 2003-04-04
First Publication Date 2005-05-19
Grant Date 2011-07-05
Owner FMC Biopolymer AS (Norway)
Inventor
  • Andersen, Peder Oscar
  • Gåseröd, Olav
  • Larsen, Christian Klein

Abstract

The present invention is directed to seamless capsules and methods for making seamless capsules having a high oil content. More specifically, the present invention is directed to seamless capsules, and methods for making seamless capsules, made from a process involving the steps of: (a) preparing an emulsion comprising oil, water, an emulsifier, and at least one of a water-soluble monovalent metal salt, polyvalent metal salt, and an acid, wherein said oil is present in an amount of at least 50% by weight of said emulsion; with the proviso that said emulsion does not contain marmelo mucilage; and (b) adding portions of said emulsion to an aqueous gelling bath comprised of at least one ionic polysaccharide, thereby encapsulating said portions of said emulsion in a polysaccharide gel membrane, and optionally (c) drying the resulting capsules by removing water. The capsule is, for example, an alignate gel. The capsules of the invention are suitable for a variety of applications, e.g. pharmaceutical, nutraceutical, veterinary, agricultural, cosmetic, or food applications.

IPC Classes  ?

  • A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K 9/52 - Sustained or differential release type
  • A61K 9/66 - Sustained or differential release type containing emulsions, dispersions or solutions